Pharma's Almanac TV
PA TV
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2021 Cell & Gene Therapy Report
2021 Monoclonal Antibody & Recombinant Protein Market Report
2021 Sterile Drug Market Report
2021 API Market Report
2020 OSD Market Report
Community
Company A to Z
More+
Staffing
Media Kit
Formulation
92 Articles Available
1
4
Can't find what you're looking for? Try our
advanced search
.
Orally Disintegrating Tablets
A Revolutionary Excipient Platform for Super-Fast Disintegrating ODTs
PAO-07-21-CL-03
3D Printing
Transferring 3D Printing into Pharma: The Journey Has Begun
PAO-07-21-CL-04
Hot Melt Extrusion
Solving Solubility Challenges with a Polyvinyl Alcohol Excipient and Hot Melt Extrusion
PAP-Q4-20-CL-016
Orally Disintegrating Tablets
Qualifying ODT Excipient Systems Beyond Disintegration Performance
PAO-10-20-CL-03
Lipid Excipients
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strategies
PAP-Q3-20-CL-024
Clinical Supply
Getting Your Biologic to Clinic Faster and More Efficiently
PAP-Q3-20-CL-011
Thin-Film Freezing
Enhancing Drug Delivery with Thin-Film Freezing Technology
PAP-Q3-20-CL-030
Drug Delivery
COVID-19 Vaccine Delivered By Skin Patch Shows Promise
PR-M04-20-NI-012
Excipients
New Mannitol Formulations Are a Gem of a Collection
PAP-Q1-20-CL-004
CBD
Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument
PR-M01-20-NI-045
Liposome Formulations
FUJIFILM Toyama Chemical Announces Completion of Japan’s First Manufacturing Facility for Commercial Liposome Formulations
PR-M12-19-NI-015
Oral Peptides
Advances in the Oral Delivery of Peptides
PAP-Q4-19-CL-001
License Agreement
SeraNovo Enters into License Agreement with Carna Biosciences for Development of Oral Formulation of Carna's Kinase Inhibitor
PR-M10-19-NI-046
Semisolid Dosage Forms
Supporting Commercial Manufacturing of Semisolid Dosage Forms
PAP-Q3-19-CL-034
Drug Development
Looking Beyond Current Treatments for CNS Diseases and Disorders
PAP-Q3-19-CL-036
Thermal Stability
Stabilizing and Protecting Biologic Formulations
PAP-Q3-19-CL-017
Commercialization
Supporting Commercialization with Specialized Technologies
PAP-Q2-2019-CL-034
Formulation
Taking Extra Care with Formulation
PAP-Q2-2019-CL-016
Formulation
Developing and Characterizing DPI Formulations for Biologics
PAP-Q1-2019-CL-002
Virtual Panel
Reprioritizing to Bring FY2020 into Focus
PAP-Q1-2019-CL-032
The Ideal Capsule Supplier: Using A Holistic Approach to Facilitate Customer Success
Formulation
The Coming of Age of Amorphous Solid Dispersions
PAP-Q4-18-CL-004
Influenza
FluMist Shipped by AstraZeneca
PAO-M10-18-NI-007
Collaboration
Context Therapeutics Signs Strategic Research Collaborations for Apristor® (onapristone extended release) With Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer Fields
PR-M08-18-NI-086
1
4
»
